HRP20120688T1 - Re“im doziranja u liječenju traumatske ozljede mozga progesteronom - Google Patents
Re“im doziranja u liječenju traumatske ozljede mozga progesteronom Download PDFInfo
- Publication number
- HRP20120688T1 HRP20120688T1 HRP20120688TT HRP20120688T HRP20120688T1 HR P20120688 T1 HRP20120688 T1 HR P20120688T1 HR P20120688T T HRP20120688T T HR P20120688TT HR P20120688 T HRP20120688 T HR P20120688T HR P20120688 T1 HRP20120688 T1 HR P20120688T1
- Authority
- HR
- Croatia
- Prior art keywords
- progesterone
- period
- use according
- subject
- level
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract 98
- 229960003387 progesterone Drugs 0.000 title claims abstract 49
- 239000000186 progesterone Substances 0.000 title claims abstract 49
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract 6
- 230000009529 traumatic brain injury Effects 0.000 title claims abstract 6
- 238000001802 infusion Methods 0.000 claims abstract 18
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 10
- 238000001990 intravenous administration Methods 0.000 claims abstract 7
- 210000002966 serum Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Progesteron namijenjen upotrebi liječenju traumatske ozljede mozga, naznačen time ®to se navedeni progesteron pripravlja za primjenu na ljudskom subjektu u najmanje jednom ciklusu terapije, gdje se navedeni ciklus terapije sastoji u primjeni terapijski djelotvornog dvorazinskog intravenskog re·ima doziranja progesterona, gdje navedeni dvorazinski re·im doziranja uključuje prvi period od najmanje 1 sata, gdje se na subjektu primijenjuje vi®a infuzijska doza progesterona po satu od otprilike 0,1 mg/kg/hr do otprilike 7,1 mg/kg/hr, za čim slijedi drugi period, gdje se na navedenom subjektu primijenjuje ni·a infuzijska doza progesterona po satu od otprilike 0,05 mg/kg/hr do otprilike 5 mg/kg/hr. Patent sadr·i jo® 25 patentnih zahtjeva.
Claims (26)
1. Progesteron namijenjen upotrebi liječenju traumatske ozljede mozga, naznačen time što se navedeni progesteron pripravlja za primjenu na ljudskom subjektu u najmanje jednom ciklusu terapije, gdje se navedeni ciklus terapije sastoji u primjeni terapijski djelotvornog dvorazinskog intravenskog režima doziranja progesterona, gdje navedeni dvorazinski režim doziranja uključuje prvi period od najmanje 1 sata, gdje se na subjektu primijenjuje viša infuzijska doza progesterona po satu od otprilike 0,1 mg/kg/hr do otprilike 7,1 mg/kg/hr, za čim slijedi drugi period, gdje se na navedenom subjektu primijenjuje niža infuzijska doza progesterona po satu od otprilike 0,05 mg/kg/hr do otprilike 5 mg/kg/hr.
2. Progesteron namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što prvi period uključuje infuzijsku dozu progesterona od otprilike 0,71 mg/kg/hr.
3. Progesteron namijenjen upotrebi liječenju traumatske ozljede mozga, naznačen time što se navedeni progesteron pripravlja za primjenu na ljudskom subjektu u najmanje jednom ciklusu terapije, gdje se navedeni ciklus terapije sastoji u primjeni terapijski djelotvornog dvorazinskog intravenskog režima doziranja progesterona, gdje navedeni dvorazinski režim doziranja uključuje prvi period, gdje se na subjektu primijenjuje viša infuzijska doza progesterona po satu, za čim slijedi drugi period, gdje se na navedenom subjektu primijenjuje niža infuzijska doza progesterona po satu od otprilike 0,05 mg/kg/hr do otprilike 5 mg/kg/hr, te gdje prvi period uključuje bolusnu injekciju.
4. Progesteron namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačena time što drugi period uključuje infuzijsku dozu od otprilike 0,5 mg/kg/hr.
5. Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što drugi period traje otprilike 24 sat do otprilike 120 sat.
6. Progesteron namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačena time što drugi period traje otprilike 71 sat.
7. Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što prvi period uključuje infuzijsku dozu progesterona od otprilike 0,71 mg/kg/hr, a drugi period uključuje infuzijsku dozu od otprilike 0,5 mg/kg/hr, gdje prvi period traje otprilike 1 sat, a drugi period traje otprilike 71 sat.
8. Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dvorazinski intravenski režim doziranja progesterona resultira razinom progesterona u serumu kod navedenog subjekta od otprilike 100 ng/ml do otprilike 2000 ng/ml.
9. Progesteron namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je razina progesterona u serumu otprilike 200 ng/ml do otprilike 750 ng/ml.
10. Progesteron namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je razina progesterona u serumu otprilike 350 ng/ml do otprilike 450 ng/ml.
11. Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dodatno uključuje treći period, gdje se navedeni treći period sastoji u progresivno smanjivanoj primjeni progesterona na subjektu.
12. Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su prvi i drugi period kontinuirani.
13. Progesteron namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što su prvi i drugi period diskontinuirani.
14. Upotreba progesterona u pripravi medikamenta za liječenje traumatske ozljede mozga kod ljudskog subjekta, naznačena time što se navedeni medikament pripravlja za primjenu na ljudskom subjektu u najmanje jednom ciklusu terapije, gdje se navedeni ciklus terapije sastoji u primjeni terapijski djelotvornog dvorazinskog intravenskog režima doziranja progesterona, gdje navedeni dvorazinski režim doziranja uključuje prvi period od najmanje 1 sata, gdje se na subjektu primijenjuje viša infuzijska doza progesterona po satu od otprilike 0,1 mg/kg/hr do otprilike 7,1 mg/kg/hr, za čim slijedi drugi period, gdje se na navedenom subjektu primijenjuje niža infuzijska doza progesterona po satu od otprilike 0,05 mg/kg/hr do otprilike 5 mg/kg/hr.
15. Upotreba u skladu s patentnim zahtjevom 14, naznačena time što prvi period uključuje infuzijsku dozu progesterona od otprilike 0,71 mg/kg/hr.
16. Upotreba progesterona u pripravi medikamenta za liječenje traumatske ozljede mozga kod ljudskog subjekta, naznačena time što se navedeni medikament pripravlja za primjenu na ljudskom subjektu u najmanje jednom ciklusu terapije, gdje se navedeni ciklus terapije sastoji u primjeni terapijski djelotvornog dvorazinskog intravenskog režima doziranja progesterona, gdje navedeni dvorazinski režim doziranja uključuje prvi period, gdje se na subjektu primijenjuje viša infuzijska doza progesterona po satu, za čim slijedi drugi period, gdje se na navedenom subjektu primijenjuje niža infuzijska doza progesterona po satu od otprilike 0,05 mg/kg/hr do otprilike 5 mg/kg/hr, te gdje prvi period uključuje bolusnu injekciju.
17. Upotreba u skladu s patentnim zahtjevom 14 ili 16, naznačena time što drugi period uključuje infuzijsku dozu od otprilike 0,5 mg/kg/hr.
18. Upotreba u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačena time što drugi period traje otprilike 24 sat do otprilike 120 sat.
19. Upotreba u skladu s patentnim zahtjevom 18, naznačena time što drugi period traje otprilike 71 sat.
20. Upotreba u skladu s bilo kojim od patentnih zahtjeva 14 do 19, naznačena time što prvi period uključuje infuzijsku dozu progesterona od otprilike 0,71 mg/kg/hr, a drugi period uključuje infuzijsku dozu od otprilike 0,5 mg/kg/hr, gdje prvi period traje otprilike 1 sat, a drugi period traje otprilike 71 sat.
21. Upotreba u skladu s bilo kojim od patentnih zahtjeva 14 do 20, naznačena time što dvorazinski intravenski režim doziranja progesterona resultira razinom progesterona u serumu kod navedenog subjekta od otprilike 100 ng/ml do otprilike 2000 ng/ml.
22. Upotreba u skladu s patentnim zahtjevom 21, naznačen time što je razina progesterona u serumu otprilike 200 ng/ml do otprilike 750 ng/ml.
23. Upotreba u skladu s patentnim zahtjevom 22, naznačen time što je razina progesterona u serumu otprilike 350 ng/ml do otprilike 450 ng/ml.
24. Upotreba u skladu s bilo kojim od patentnih zahtjeva 14 do 23, naznačena time što dodatno uključuje treći period, gdje se navedeni treći period sastoji u progresivno smanjivanoj primjeni progesterona na subjektu.
25. Upotreba u skladu s bilo kojim od patentnih zahtjeva 14 do 24, naznačen time što su prvi i drugi period kontinuirani.
26. Upotreba u skladu s bilo kojim od patentnih zahtjeva 14 do 24, naznačen time što su prvi i drugi period diskontinuirani.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66472805P | 2005-03-24 | 2005-03-24 | |
| US72966305P | 2005-10-24 | 2005-10-24 | |
| PCT/US2006/010797 WO2006102596A2 (en) | 2005-03-24 | 2006-03-24 | Dosage regimen for the treatment of a traumatic brain injury with progesterone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120688T1 true HRP20120688T1 (hr) | 2012-09-30 |
Family
ID=36987966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110198T HRP20110198T1 (hr) | 2005-03-24 | 2011-03-17 | Indikacija doziranja progesterona u liječenju traumatske ozljede mozga |
| HRP20120688TT HRP20120688T1 (hr) | 2005-03-24 | 2012-08-30 | Re“im doziranja u liječenju traumatske ozljede mozga progesteronom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110198T HRP20110198T1 (hr) | 2005-03-24 | 2011-03-17 | Indikacija doziranja progesterona u liječenju traumatske ozljede mozga |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20090221544A1 (hr) |
| EP (5) | EP1868614B1 (hr) |
| JP (5) | JP5394059B2 (hr) |
| AT (2) | ATE520404T1 (hr) |
| AU (2) | AU2006226774B2 (hr) |
| CA (2) | CA2601715C (hr) |
| CY (2) | CY1111478T1 (hr) |
| DE (1) | DE602006020353D1 (hr) |
| DK (2) | DK1868614T3 (hr) |
| ES (2) | ES2392454T3 (hr) |
| HK (3) | HK1112579A1 (hr) |
| HR (2) | HRP20110198T1 (hr) |
| PL (2) | PL2030622T3 (hr) |
| PT (2) | PT2030622E (hr) |
| RS (1) | RS52471B (hr) |
| WO (2) | WO2006102644A2 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473687B2 (en) | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| EP1868614B1 (en) * | 2005-03-24 | 2012-08-08 | Emory University | Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| EP2052724A1 (en) * | 2007-10-26 | 2009-04-29 | sanofi-aventis | Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel |
| AU2009219230A1 (en) | 2008-02-26 | 2009-09-03 | Emory University | Steroid analogues for neuroprotection |
| EP2331571B1 (en) | 2008-09-18 | 2015-08-26 | Northwestern University | Nmda receptor modulators and uses thereof |
| US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| US10993879B2 (en) * | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| US20110262502A1 (en) * | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| US10987361B2 (en) | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| ES2773079T3 (es) | 2010-02-08 | 2020-07-09 | Shenzhen Evergreen Therapeutics Co Ltd | Métodos para el uso de progestágeno como sensibilizador de glucocorticoides |
| TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
| SG10202010665YA (en) * | 2011-04-27 | 2020-11-27 | Univ Northwestern | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| LT2806877T (lt) * | 2012-01-23 | 2019-12-10 | Sage Therapeutics Inc | Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą |
| US20130210785A1 (en) | 2012-02-15 | 2013-08-15 | Emory University | Progesterone analogs and uses related thereto |
| CN110251463A (zh) | 2012-02-29 | 2019-09-20 | 贝朗医疗有限公司 | 含激素的乳液 |
| RU2498826C1 (ru) * | 2012-05-14 | 2013-11-20 | Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук | Способ лечения больных с черепно-мозговой травмой |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| AU2014212501A1 (en) | 2013-01-29 | 2015-07-30 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| EA201591404A1 (ru) | 2013-01-29 | 2016-01-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| AU2014212485C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CA2898863A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| HUE043843T2 (hu) | 2013-01-29 | 2019-09-30 | Aptinyx Inc | Spiro-laktám NMDA receptor modulátorok és azok alkalmazása |
| EP3978507A1 (en) | 2013-08-12 | 2022-04-06 | Emory University | Progesterone phosphate analogs and uses related thereto |
| US10231979B2 (en) * | 2015-08-07 | 2019-03-19 | Indiana University Research And Technology Corporation | Modulation of inflammation using progesterone metabolites |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CA3024606C (en) | 2016-05-19 | 2019-09-03 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| BR112019001926A2 (pt) | 2016-08-01 | 2019-08-06 | Aptinyx Inc | moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes |
| CA3031534C (en) | 2016-08-01 | 2023-10-17 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP7032378B2 (ja) | 2016-08-01 | 2022-03-08 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| BR112019001768A2 (pt) | 2016-08-01 | 2019-06-11 | Aptinyx Inc | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos |
| EP3490990B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda modulators and methods of using same |
| WO2019152687A1 (en) | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| WO2023102149A1 (en) * | 2021-12-02 | 2023-06-08 | MarvelBiome, Inc. | Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions |
| WO2024059056A1 (en) * | 2022-09-12 | 2024-03-21 | Emory University | Methods of managing traumatic brain injury |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5217085A (en) | 1975-07-30 | 1977-02-08 | Ono Pharmaceut Co Ltd | Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes |
| US4404366A (en) * | 1980-05-06 | 1983-09-13 | Miles Laboratories, Inc. | Beta-galactosyl-umbelliferone-labeled hapten conjugates |
| US4369250A (en) | 1981-07-31 | 1983-01-18 | Sherwood Medical Industries Inc. | Fatty acid determination |
| US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| AU609927B2 (en) | 1987-08-25 | 1991-05-09 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| USRE35517E (en) * | 1987-08-25 | 1997-05-20 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5512429A (en) | 1989-09-19 | 1996-04-30 | British Technology Group Limited | Assay for enzyme activity |
| GB9105707D0 (en) | 1991-03-18 | 1991-05-01 | Wilton David C | Assay |
| US5114388A (en) * | 1991-07-26 | 1992-05-19 | True Fitness Technology, Inc. | Stair simulator exerciser with adjustable incline |
| US5212167A (en) * | 1991-09-12 | 1993-05-18 | Trustees Of Boston University | Modulation of receptor-mediated ion transport |
| US5206415A (en) * | 1991-12-20 | 1993-04-27 | Washington University | Tricyclic steroid analogs |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| ATE275957T1 (de) * | 1993-01-19 | 2004-10-15 | Endorech Inc | Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron |
| DE4311870C2 (de) | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
| US5763431A (en) * | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
| AU7569194A (en) * | 1993-08-20 | 1995-03-21 | Meyer B. Jackson | Method for regulating neuropeptide hormone secretion |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
| US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| US5837544A (en) * | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
| ES2235187T3 (es) * | 1995-06-06 | 2005-07-01 | Euro-Celtique S.A. | Esteroides neuroactivos de las series del androstano y el pregnano. |
| EP0778768B1 (en) * | 1995-06-09 | 2004-05-26 | Euroceltique S.A. | Formulations and methods for providing prolonged local anesthesia |
| US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| JP2000513336A (ja) | 1996-05-22 | 2000-10-10 | ディバーシファイド ファーマシューティカルズ，インコーポレーテッド | 薬物の経皮送達のための組成物、方法及びデバイス |
| US5763492A (en) * | 1996-10-01 | 1998-06-09 | Duguesne University Of The Holy Ghost | Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors |
| EP0981349B1 (en) | 1997-05-02 | 2002-11-06 | Wyeth | 5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumours and cns diseases |
| US6245757B1 (en) * | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
| US6268223B1 (en) | 1999-08-27 | 2001-07-31 | Viatech Imagin, Llc | Assay for detecting damage to the central nervous system |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1868614B1 (en) * | 2005-03-24 | 2012-08-08 | Emory University | Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| US7473687B2 (en) * | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
-
2006
- 2006-03-24 EP EP06748657A patent/EP1868614B1/en active Active
- 2006-03-24 DK DK06748657.1T patent/DK1868614T3/da active
- 2006-03-24 EP EP12163432A patent/EP2494976A1/en not_active Withdrawn
- 2006-03-24 WO PCT/US2006/010984 patent/WO2006102644A2/en active Application Filing
- 2006-03-24 ES ES06748657T patent/ES2392454T3/es active Active
- 2006-03-24 EP EP11177154.9A patent/EP2431042B1/en active Active
- 2006-03-24 DK DK08167618.1T patent/DK2030622T3/da active
- 2006-03-24 US US11/909,276 patent/US20090221544A1/en not_active Abandoned
- 2006-03-24 CA CA2601715A patent/CA2601715C/en not_active Expired - Fee Related
- 2006-03-24 AU AU2006226774A patent/AU2006226774B2/en not_active Ceased
- 2006-03-24 JP JP2008503262A patent/JP5394059B2/ja not_active Expired - Fee Related
- 2006-03-24 PT PT08167618T patent/PT2030622E/pt unknown
- 2006-03-24 DE DE602006020353T patent/DE602006020353D1/de active Active
- 2006-03-24 AT AT06739662T patent/ATE520404T1/de not_active IP Right Cessation
- 2006-03-24 WO PCT/US2006/010797 patent/WO2006102596A2/en active Application Filing
- 2006-03-24 PT PT06748657T patent/PT1868614E/pt unknown
- 2006-03-24 PL PL08167618T patent/PL2030622T3/pl unknown
- 2006-03-24 EP EP06739662A patent/EP1871382B1/en active Active
- 2006-03-24 EP EP08167618A patent/EP2030622B1/en active Active
- 2006-03-24 AU AU2006226811A patent/AU2006226811B2/en not_active Ceased
- 2006-03-24 ES ES11177154T patent/ES2428313T3/es active Active
- 2006-03-24 CA CA2602950A patent/CA2602950C/en not_active Expired - Fee Related
- 2006-03-24 AT AT08167618T patent/ATE499104T1/de active
- 2006-03-24 US US11/909,278 patent/US20090325920A1/en not_active Abandoned
- 2006-03-24 RS RS20120433A patent/RS52471B/en unknown
- 2006-03-24 JP JP2008503227A patent/JP5295755B2/ja not_active Expired - Fee Related
- 2006-03-24 PL PL06748657T patent/PL1868614T3/pl unknown
-
2008
- 2008-06-25 HK HK08107067.5A patent/HK1112579A1/xx not_active IP Right Cessation
- 2008-06-30 HK HK08107230.7A patent/HK1112581A1/xx not_active IP Right Cessation
-
2009
- 2009-08-14 HK HK09107489.4A patent/HK1128242A1/xx not_active IP Right Cessation
-
2011
- 2011-03-17 HR HR20110198T patent/HRP20110198T1/hr unknown
- 2011-05-20 CY CY20111100496T patent/CY1111478T1/el unknown
- 2011-08-17 JP JP2011178655A patent/JP2011225629A/ja not_active Withdrawn
-
2012
- 2012-04-24 US US13/454,503 patent/US20120245133A1/en not_active Abandoned
- 2012-07-16 US US13/550,148 patent/US8614203B2/en active Active
- 2012-08-30 HR HRP20120688TT patent/HRP20120688T1/hr unknown
- 2012-10-25 CY CY20121101012T patent/CY1113253T1/el unknown
-
2013
- 2013-07-12 JP JP2013146680A patent/JP2013234191A/ja not_active Withdrawn
- 2013-12-20 JP JP2013263682A patent/JP5496407B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120688T1 (hr) | Re“im doziranja u liječenju traumatske ozljede mozga progesteronom | |
| Kurth et al. | Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with'on‐off'fluctuations | |
| Berger | Subcutaneous immunoglobulin replacement in primary immunodeficiencies | |
| Breymann et al. | Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| EP2433650A3 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
| SG170058A1 (en) | Methods of treating inflammatory and autoimmune diseases with natalizumab | |
| NZ741494A (en) | Methods of reducing eosinophil levels | |
| HRP20161284T1 (hr) | METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM | |
| WO2008039898A3 (en) | Methods for the treatment of a traumatic central nervous system injury | |
| JP2015187125A5 (hr) | ||
| HRP20120349T1 (hr) | Formulacija glatiramer acetata smanjenog volumenai postupci davanja | |
| KR101900520B1 (ko) | 복합 조성물 | |
| YU30002A (sh) | Upotreba dipiridamola ili mopidamola u pripremanju leka za lečenje i prevenciju mikrocirkulacionih poremećaja koji zavise od fibrina | |
| WO2007038428A3 (en) | Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds | |
| WO2005120542A3 (en) | Methods of treating disease with random copolymers | |
| CN105209044B (zh) | 用于疼痛病症的治疗性米氮平组合物 | |
| WO2009005046A1 (ja) | ミゾリビンを含有する潰瘍性大腸炎治療薬 | |
| JP2005529152A5 (hr) | ||
| Love et al. | Glucagon therapy in the treatment of symptomatic bradycardia | |
| JP2001523635A5 (hr) | ||
| Cohen | Use of a GABA-transaminase agonist for treatment of infantile autism | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| Lai et al. | Burning-Feet Syndrome: Case Due to Malabsorption and Responding to Riboflavine | |
| Scott | Advances in the medical management of rheumatoid arthritis |